October 17, 2024
Request for Information: Medicare $2 Drug List Model – Respond by December 9
In response to an Executive Order to lower prescription drug costs, the Centers for Medicare & Medicaid Services (CMS) developed a model to test whether a simpler approach to offering low-cost, clinically important generic drugs can improve medication adherence, lead to better health outcomes, and improve satisfaction with the Part D prescription drug benefit for people with Medicare and for prescribers.
This RFI aims to obtain input from a broad range of interested parties to support continued development of the model. CMS’ primary areas of interest include:
- Drug List Development Process;
- Maximizing Plan Participation;
- CMS Outreach Efforts;
- Part D Sponsor Outreach and Education Efforts for Beneficiaries;
- Assessment of Model Impact;
- Drug List Modifications.
CMS is interested in hearing from all stakeholders, including, but not limited to:
- Medicare beneficiaries
- Advocates
- Medicare Part D plan sponsors
- Pharmacy benefit managers
- Prescribers
- Pharmacists
- Pharmacies
- Policy experts
- Researchers
- Drug manufacturers
- Wholesalers
- Distributors
- All other interested parties
Click Here to Read More
Click Here to Read Executive Order
Process for Submitting Response:
- Deadline to respond: December 9, 2024, 11:59 p.m. PST
- Comments can be submitted here